ABSTRACT
INTRODUCTION
Effective screening for trisomies 21, 18 and 13 is provided by the first-trimester combined test, with detection rates (DR) of 90%, 97% and 92%, at a false-positive rate (FPR) of 4% 1 . Recent evidence suggests that the performance of screening can be further improved by analysis of cell-free (cf) DNA in maternal blood; a meta-analysis of clinical validation and implementation studies has reported that, with cfDNA testing, the DR for trisomies 21, 18 and 13 were 99%, 96% and 91%, respectively, at an overall FPR of 0.35% 2 . However, the cfDNA test is too expensive for universal screening and is, therefore, likely to be offered to a subgroup of women identified by the combined test as being at increased risk for trisomy. In the UK, the National Screening Committee (NSC) recommended that the cfDNA test be offered as an alternative to invasive testing to women with a risk ≥ 1 in 100 derived from the combined test at the time of screening 3 . In addition, pregnancies with fetal nuchal translucency thickness (NT) ≥ 3.5 mm and those with major defects detected at the 11-13-week scan should be examined at specialist units for further management. We have reported previously that many fetal defects can be diagnosed by the first-trimester scan but, specifically, alobar holoprosencephaly, exomphalos and megacystis are always detectable 4 . The aims of this large screening study were to examine the prevalence of alobar holoprosencephaly, exomphalos, megacystis and NT ≥ 3.5 mm, the incidence and types of associated chromosomal abnormalities in affected cases and the overall impact of their presence on the rate of invasive testing and performance of screening for chromosomal abnormalities.
METHODS
This was a prospective screening study for trisomies 21, 18 and 13 by analysis of a combination of maternal age, fetal NT, fetal heart rate and serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A at 11 + 0 to 13 + 6 weeks' gestation in women booking for routine pregnancy care at King 5 . The eligibility criteria were singleton pregnancy with a live fetus at the 11-13-week scan.
Maternal demographic characteristics, sonographic measurements and biochemical results were recorded in a computer database along with information on any anomalous findings. Karyotype results and details on pregnancy outcomes were added to the database as soon as they became available. Diagnosis of chromosomal abnormality was based on prenatal fetal karyotyping following chorionic villus sampling or amniocentesis or postnatal karyotyping of neonatal blood; phenotypically normal neonates were assumed to be chromosomally normal.
The diagnosis of alobar holoprosencephaly was based on fusion of the anterior horns of the lateral ventricles and absence of the butterfly sign in a cross-sectional view of the fetal brain 6 . Exomphalos was diagnosed if there was herniation of bowel or liver in the base of the umbilical cord. Megacystis was defined as an enlarged bladder with a longitudinal diameter of ≥ 7 mm 7 .
RESULTS
During the study period, we examined 115 838 singleton pregnancies. We excluded 6856 (5.9%) cases because they had missing outcome data (n = 5150) or the fetal karyotype was unknown and the pregnancy resulted in termination, miscarriage or stillbirth (n = 1706).
In the study population of 108 982 cases, median maternal age was 31.5 (interquartile range (IQR), 27.2-35.2) years and median gestational age was 12.7 (IQR, 12.3-13.1) weeks 1 . There were 108 112 (99.2%) cases with normal fetal karyotype or birth of a phenotypically normal neonate and 870 (0.8%) cases with abnormal karyotype, including trisomy 21 (n = 432), trisomy 18 (n = 166), trisomy 13 (n = 56), monosomy X (n = 63), triploidy (n = 35) or other aneuploidy (n = 118 i.e. sex chromosome aneuploidies (n = 15), chromosomal deletions or duplications (n = 68), mosaic sex aneuploidies (n = 11), mosaic deletions or duplications (n = 6) and mosaic trisomies of chromosomes 2, 4, 8, 9, 13, 16, 21 or 22 (n = 18)).
The prevalence of fetal alobar holoprosencephaly, exomphalos, megacystis and NT ≥ 3.5 mm was 1 in 2945, 1 in 419, 1 in 1345 and 1 in 119, respectively. In the cases of megacystis, bladder length was 7-15 mm in 63 (77.8%) cases and > 15 mm in 18 (22.2%). Exomphalos containing liver was observed in 33 (12.7%) cases and the prevalence was unrelated to fetal crown-rump length (CRL). Exomphalos containing only bowel was observed in 227 (87.3%) cases and the prevalence decreased from 1 in 114 for CRL 45-54 mm to 1 in 953 for CRL 55-84 mm. The incidence and types of associated chromosomal abnormalities for each fetal defect and for an increased NT are shown in Table 1 . Chromosomal abnormalities were observed in 78.4% of cases of holoprosencephaly, 40.8% of exomphalos, 18.5% of megacystis and 48.5% of those with NT ≥ 3.5 mm. In cases of exomphalos containing bowel only, the incidence of chromosomal abnormalities was similar between those with CRL of 45-54 mm (41.4%) and those with CRL of 55-84 mm (38.4%). The incidence of chromosomal abnormalities in cases of megacystis was similar between those with bladder length of 7-15 mm (19.0%) and those with bladder length > 15 mm (16.7%). The most common chromosomal abnormality associated with holoprosencephaly was trisomy 13, with exomphalos and megacystis was trisomy 18 and with increased NT was trisomy 21. The incidence of chromosomal abnormalities in the presence of each defect was analyzed according to the estimated risk from the combined test (Table 2) . For holoprosencephaly, exomphalos containing liver, megacystis and increased NT, all cases of trisomies 21, 18 and 13 were in the subgroups with an estimated risk for these trisomies from the combined test of ≥ 1 in 100. In the cases of exomphalos containing bowel only, the total rate of trisomies 21, 18 and 13 was 70.2% in those with an estimated risk from the combined test of ≥ 1 in 100 and only 2.4% in those with a risk of < 1 in 100. Similarly, the rate of chromosomal abnormalities other than trisomies 21, 18 and 13 in fetuses with holoprosencephaly, exomphalos and increased NT was substantially higher in those with an estimated risk from the combined test of ≥ 1 in 100 than in those with a risk of < 1 in 100.
Fetal karyotyping performed because of major fetal defects or increased NT would potentially detect 57% of all chromosomal abnormalities at an invasive testing rate of 1.1%. If karyotyping was restricted to the subgroup of cases with an estimated risk for trisomies from the combined test of ≥ 1 in 100, 56% of all chromosomal abnormalities would be detected at an invasive testing rate of 0.8%.
DISCUSSION

Main findings
The findings of this large prospective study at 11-13 weeks' gestation demonstrate that the prevalence of alobar holoprosencephaly, exomphalos, megacystis or NT ≥ 3.5 mm is about 1% and, in this group of fetuses, the incidence of a wide range of chromosomal abnormalities is more than 40%. Chromosomal abnormalities were observed in 78% of cases of holoprosencephaly, 41% of exomphalos, 19% of megacystis and 49% with NT ≥ 3.5 mm. The most common chromosomal abnormality associated with holoprosencephaly was trisomy 13, with exomphalos and megacystis was trisomy 18 and with increased NT was trisomy 21. In cases of exomphalos containing only bowel, the incidence of chromosomal abnormalities was similar between those with CRL of 45-54 mm and those with CRL of 55-84 mm and in cases of megacystis, the incidence was similar between those with bladder length of 7-15 mm and those with bladder length of > 15 mm.
The rate of trisomies 21, 18 and 13 and other chromosomal abnormalities in fetuses with major fetal defects or increased NT was substantially higher in those with an estimated risk from the combined test of ≥ 1 in 100 than in those with a risk of < 1 in 100. Fetal karyotyping performed because of major fetal defects or increased NT would potentially detect 57% of all chromosomal abnormalities at an invasive testing rate of 1.1%. If in the presence of these defects or increased NT, the decision in favor or against invasive testing was based on the results of the combined test, the rate of invasive testing would be reduced from 1.1% to 0.8% and the detection rate of chromosomal abnormalities would be reduced from 57% to 56%.
Study limitations
The main limitation of the study relates to ascertainment of pregnancy outcome. Unlike for trisomies 21, 18 and 13, most neonates with sex chromosome aneuploidies and those in the heterogeneous group classified as other chromosomal abnormalities are often phenotypically normal. Consequently, studies that do not involve karyotyping of the whole population will inevitably underestimate the true prevalence of these abnormalities and overestimate the potential sensitivity of a prenatal screening test 8 .
Comparison with findings of previous studies
The findings on the prevalence of major defects and associations with chromosomal abnormalities are in agreement with our results from a previous screening study at 11-13 weeks' gestation, involving 57 119 pregnancies, and several other small studies 9 .
Implications for practice
Holoprosencephaly, exomphalos containing liver, megacystis with bladder length > 15 mm and NT ≥ 3.5 mm are associated with a high rate of perinatal death and high incidence of chromosomal abnormalities and genetic syndromes; in these conditions, invasive testing for fetal karyotype is an essential step in the investigation that would not only help in defining the prognosis for the index pregnancy but also the risk of recurrence in subsequent pregnancies. In contrast, megacystis with bladder length of 7-15 mm and exomphalos containing bowel only, particularly for those with CRL of 45-54 mm, are transient findings with good prognosis 9 and it could be argued that, in these cases, the decision in favor or against invasive testing should be based on the results of the combined test. Alternatively, these conditions could be investigated by cfDNA testing.
